A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

NCT03794440 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

595

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sintilimab
DRUG: IBI305
DRUG: Sorafenib

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.